Clinical Development - Kintara Therapeutics announced preliminary topline results for VAL-083, which did not perform better than current standards of care in glioblastoma, leading to the termination of its development[107]. - The company received a $2,000 grant from the NIH to support the clinical development of REM-001, which will fund the majority of expenses related to a 15-patient study[109]. - In clinical studies, REM-001 Therapy achieved a complete response in approximately 80% of evaluable tumor sites treated for cutaneous metastatic breast cancer[111]. - The FDA granted Fast Track Designation for REM-001 in CMBC, indicating its potential significance in treating this condition[117]. - The company initiated an open label study for REM-001, evaluating a 0.8 mg dose in CMBC patients, with the primary endpoint being the Best Overall Objective Response Rate[108]. - Kintara has opened enrollment for the REM-001 Study at Memorial Sloan Kettering Cancer Center, having treated 2 patients as of May 14, 2024[109]. Financial Performance - As of March 31, 2024, cash and cash equivalents increased to $6,351,000 from $1,535,000 as of June 30, 2023, representing a growth of 314%[127]. - Research and development expenses decreased by 70% to $592,000 for the three months ended March 31, 2024, compared to $2,005,000 for the same period in 2023[135]. - General and administrative expenses increased by 15% to $1,493,000 for the three months ended March 31, 2024, compared to $1,297,000 for the same period in 2023[135]. - The net loss for the three months ended March 31, 2024, was $2,011,000, a reduction of 38% from the net loss of $3,264,000 for the same period in 2023[135]. - For the nine months ended March 31, 2024, research and development expenses decreased by 65% to $2,562,000 from $7,235,000 for the same period in 2023[142]. - The net loss for the nine months ended March 31, 2024, was $5,996,000, a decrease of 53% compared to the net loss of $11,314,000 for the same period in 2023[142]. - Cash flows from operating activities improved by 45%, with a cash outflow of $5,734,000 for the nine months ended March 31, 2024, compared to $10,357,000 for the same period in 2023[148]. - Cash flows from financing activities significantly increased by 470% to $10,570,000 for the nine months ended March 31, 2024, compared to $1,854,000 for the same period in 2023[148]. - Non-cash, share-based compensation expense for the three months ended March 31, 2024, decreased to $63,000 from $115,000 for the same period in 2023[139]. - The company received $194,000 in grant proceeds during the three months ended March 31, 2024, compared to nil in the same period in 2023[139]. - Net cash used in operating activities was $5,734 for the nine months ended March 31, 2024, a decrease from $10,357 for the same period in 2023[149]. - The company reported net losses of $5,996 for the nine months ended March 31, 2024, compared to $11,314 for the same period in 2023[149]. - Cash and cash equivalents were $6,351 as of March 31, 2024, with an accumulated deficit of $157,550[153]. - Net cash received from financing activities was $10,570 for the nine months ended March 31, 2024, significantly up from $1,854 in the same period in 2023[151]. - The company raised $10,471 in net proceeds from the sale of shares under its ATM Facility during the nine months ended March 31, 2024[154]. - The company has not generated any revenues to date and is in the clinical stage[153]. Corporate Actions - Kintara's stockholders are expected to own approximately 2.85% of the post-merger combined company, with TuHURA stockholders owning approximately 97.15% on a pro forma fully diluted basis[120]. - The merger with TuHURA is expected to close in the third calendar quarter of 2024, subject to stockholder and regulatory approval[121]. - A one-time special bonus of $327 was approved for the CEO for his service, and $93 in accrued fees was agreed to be paid to non-employee directors[122]. - The company is pursuing various financing alternatives to fund operations and maximize shareholder value, including a proposed merger with TuHURA[156]. - The company may require significant additional funding to maintain clinical trials and research and development projects[155]. - The company has no off-balance sheet arrangements[167]. - The company received approximately $2,000 in grant funding for its REM-001 project on June 28, 2023[153]. - The company received a Bid Price Notice from Nasdaq, giving it until June 10, 2024, to regain compliance with the minimum bid price requirement[107].

[PART I. - FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20-%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements.](index=3&type=section&id=Item%201.%20Financial%20Statements.) This section presents Kintara Therapeutics, Inc.'s unaudited condensed consolidated interim financial statements for the period ended December 31, 2023, including balance sheets, statements of operations, statements of stockholders' equity, and statements of cash flows, along with comprehensive notes detailing the company's operations, accounting policies, and financial position [Condensed Consolidated Interim Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Interim%20Balance%20Sheets) The company's financial position deteriorated significantly from June 30, 2023, to December 31, 2023, with substantial decreases in cash, total assets, and a shift to negative stockholders' equity, indicating a challenging financial outlook | Metric (in thousands) | December 31, 2023 | June 30, 2023 | Change | % Change | | :-------------------- | :------------------ | :------------ | :----- | :------- | | Cash and cash equivalents | $658 | $1,535 | $(877) | -57.1% | | Total current assets | $1,186 | $3,270 | $(2,084) | -63.7% | | Total assets | $1,885 | $3,979 | $(2,094) | -52.6% | | Total current liabilities | $1,870 | $3,082 | $(1,212) | -39.3% | | Total liabilities | $2,049 | $3,248 | $(1,199) | -36.9% | | Total stockholders' equity | $(164) | $731 | $(895) | -122.4% | [Condensed Consolidated Interim Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Operations) For the six months ended December 31, 2023, Kintara Therapeutics significantly reduced its net loss and expenses compared to the prior year, primarily driven by substantial decreases in research and development and general and administrative costs | Metric (in thousands, except per share) | Six months ended Dec 31, 2023 | Six months ended Dec 31, 2022 | Change | % Change | | :------------------------------------ | :---------------------------- | :---------------------------- | :----- | :------- | | Research and development | $1,970 | $5,230 | $(3,260) | -62.3% | | General and administrative | $2,011 | $2,915 | $(904) | -31.0% | | Total Expenses | $(3,981) | $(8,145) | $4,164 | -51.1% | | Net loss for the period | $(3,985) | $(8,050) | $4,065 | -50.5% | | Net loss attributable to common stockholders | $(4,162) | $(8,416) | $4,254 | -50.5% | | Basic and fully diluted loss per share | $(1.37) | $(5.42) | $4.05 | -74.7% | [Condensed Consolidated Interim Statements of Stockholders' Equity (Deficiency)](index=6&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Stockholders'%20Equity%20(Deficiency)) The company's stockholders' equity shifted from a positive balance of $731 thousand at June 30, 2023, to a deficiency of $(164) thousand by December 31, 2023, primarily due to the net loss for the period, partially offset by proceeds from common stock issuances | Metric (in thousands) | June 30, 2023 | December 31, 2023 | Change | | :-------------------- | :------------ | :---------------- | :----- | | Total stockholders' equity (deficiency) | $731 | $(164) | $(895) | | Accumulated deficit | $(151,375) | $(155,537) | $(4,162) | | Additional paid-in capital | $141,438 | $145,090 | $3,652 | | Common stock (shares) | 1,692 | 10,167 | 8,475 | | Preferred stock | $10,645 | $10,252 | $(393) | [Condensed Consolidated Interim Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Interim%20Statements%20of%20Cash%20Flows) Kintara Therapeutics significantly reduced cash used in operating activities for the six months ended December 31, 2023, compared to the prior year, while increasing cash provided by financing activities, primarily through equity issuances, despite a net decrease in cash and cash equivalents | Metric (in thousands) | Six months ended Dec 31, 2023 | Six months ended Dec 31, 2022 | Change | | :-------------------- | :---------------------------- | :---------------------------- | :----- | | Net cash used in operating activities | $(3,434) | $(8,530) | $5,096 | | Net cash used in investing activities | $(20) | $(232) | $212 | | Net cash provided by financing activities | $2,577 | $1,856 | $721 | | Decrease in cash and cash equivalents | $(877) | $(6,906) | $6,029 | | Cash and cash equivalents – end of period | $658 | $4,874 | $(4,216) | [Notes to Condensed Consolidated Interim Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Interim%20Financial%20Statements) The notes provide critical context to the financial statements, detailing the company's clinical-stage operations, significant accounting policies, and the substantial doubt about its ability to continue as a going concern. Key developments include the termination of VAL-083 development, the re-initiation of the REM-001 program with grant funding, and ongoing efforts to secure additional financing through equity issuances [1 Nature of operations, corporate history, and going concern and management plans](index=9&type=section&id=1%20Nature%20of%20operations%2C%20corporate%20history%2C%20and%20going%20concern%20and%20management%20plans) Kintara Therapeutics is a clinical-stage drug development company focused on novel cancer therapies, particularly REM-001 for CMBC. The company faces substantial doubt about its ability to continue as a going concern due to recurring losses, negative operating cash flows, and an accumulated deficit, necessitating ongoing efforts to secure additional financing - Kintara Therapeutics is a clinical-stage drug development company focused on novel cancer therapies, with REM-001 for cutaneous metastatic breast cancer (CMBC) as its late-stage therapeutic candidate[23](index=23&type=chunk) - The company reported a loss of **$3,985 thousand** and negative cash flow from operations of **$3,434 thousand** for the six months ended December 31, 2023, with an accumulated deficit of **$155,537 thousand** and cash of **$658 thousand** as of December 31, 2023[29](index=29&type=chunk) - These financial circumstances indicate substantial doubt about the company's ability to continue as a going concern within one year, leading management to pursue various financing alternatives including new equity, ATM facility, debt, and strategic partnerships[29](index=29&type=chunk)[30](index=30&type=chunk) [2 Significant accounting policies](index=11&type=section&id=2%20Significant%20accounting%20policies) This section outlines the significant accounting policies applied in preparing the condensed consolidated interim financial statements, including the retrospective restatement for a 1:50 reverse stock split, adherence to U.S. GAAP, consolidation principles, and the use of estimates for items like equity instruments, milestone liabilities, and clinical trial accruals. It also clarifies the calculation of loss per share and the treatment of government assistance - A **1:50 reverse stock split** was effected on November 10, 2022, with all common share and per share data retrospectively restated for all periods presented[33](index=33&type=chunk) - The financial statements are prepared in accordance with U.S. GAAP and include estimates for valuation of equity instruments, milestone payment liability, and clinical trial accruals, which could differ from actual results[34](index=34&type=chunk)[37](index=37&type=chunk) - Government grants are recognized when there is reasonable assurance of meeting program requirements and receipt, offsetting research and development expenses[40](index=40&type=chunk) [3 Clinical trial deposit](index=13&type=section&id=3%20Clinical%20trial%20deposit) Kintara Therapeutics terminated the development of VAL-083 due to unfavorable preliminary topline results from its glioblastoma study, settling the remaining deposit with the CRO. Concurrently, the company made a new deposit for the re-initiated REM-001 clinical trial for CMBC - The company terminated the development of VAL-083 after preliminary topline results from its registrational study for glioblastoma did not perform better than current standards of care[43](index=43&type=chunk) - The remaining **$1,075 thousand** deposit for the VAL-083 study was offset against amounts owed to the CRO, with an additional final cost of **$1,000 thousand**[43](index=43&type=chunk) - A **$114 thousand** deposit was paid to a CRO for the management of the 15-patient study of REM-001 for cutaneous metastatic breast cancer (CMBC)[44](index=44&type=chunk) [4 Clinical trials grant](index=13&type=section&id=4%20Clinical%20trials%20grant) Kintara Therapeutics was awarded a $2.0 million Small Business Innovation Research grant from the NIH to support the clinical development of REM-001 for CMBC, leading to the re-initiation of the 15-patient clinical trial. The grant is received as reimbursement for incurred expenditures - The company received a **$2,000 thousand** Small Business Innovation Research grant from the NIH to support the clinical development of REM-001 for cutaneous metastatic breast cancer (CMBC), to be received over two years[45](index=45&type=chunk) - The grant funding led to the re-initiation of the REM-001 15-patient clinical trial[45](index=45&type=chunk) - During the six months ended December 31, 2023, the company received **$210 thousand** in grant proceeds against research and development expenditures[45](index=45&type=chunk) [5 Property and equipment, net](index=13&type=section&id=5%20Property%20and%20equipment%2C%20net) The net property and equipment decreased slightly to $699 thousand at December 31, 2023, from $709 thousand at June 30, 2023, reflecting minor additions and depreciation expense | Metric (in thousands) | June 30, 2023 | December 31, 2023 | Change | | :-------------------- | :------------ | :---------------- | :----- | | Balance, Property and equipment, net | $709 | $699 | $(10) | | Additions | - | $20 | $20 | | Depreciation | - | $(30) | $(30) | [6 Related party transactions](index=15&type=section&id=6%20Related%20party%20transactions) Dr. Brown, a principal of Valent Technologies, LLC, was terminated as CSO but remains a consultant. The company assigned all rights to VAL-083 patents back to Valent, retaining a 5% royalty on future net sales. Dividends on Series A Preferred Stock, held by Valent, continued to be recorded, and related party payables to officers and directors decreased - Dr. Brown, a principal of Valent Technologies, LLC, was terminated as Chief Scientific Officer due to cost-cutting measures but continues as a consultant[49](index=49&type=chunk) - The company assigned all rights to VAL-083 patents back to Valent, retaining a **5% royalty** on Valent's subsequent commercialization of VAL-083[50](index=50&type=chunk)[99](index=99&type=chunk) - Series A Preferred Stock dividends of **$4 thousand** were recorded for the six months ended December 31, 2023, payable to Valent[51](index=51&type=chunk) - Related party payables to officers and directors decreased from **$298 thousand** at June 30, 2023, to **$148 thousand** at December 31, 2023[52](index=52&type=chunk) [7 Stockholders' equity](index=15&type=section&id=7%20Stockholders'%20equity) This section details changes in the company's equity, including preferred stock conversions and dividends, common stock issuances through ATM and equity line facilities, and activity related to stock options, restricted stock units, and warrants. Significant common stock issuances occurred in the latter half of 2023 and early 2024 to raise capital - The company issued **8,013 shares** of common stock for **$2,579 thousand** in net proceeds under its ATM Facility from October 31 to December 31, 2023, with an additional **$6,108 thousand** raised from **28,870 shares** from January 1 to February 12, 2024[61](index=61&type=chunk)[64](index=64&type=chunk)[94](index=94&type=chunk) - Series C Preferred Stock dividends of **$173 thousand** were recorded for the six months ended December 31, 2023, payable in common stock[55](index=55&type=chunk)[140](index=140&type=chunk) - Stock option expense for the six months ended December 31, 2023, was **$325 thousand**, with **$603 thousand** in unrecognized compensation expense remaining[81](index=81&type=chunk) [8 Supplementary statement of cash flows information](index=27&type=section&id=8%20Supplementary%20statement%20of%20cash%20flows%20information) This section provides details on non-cash investing and financing transactions, including Series C Preferred Stock common stock dividends and subscriptions receivable, which are important for a complete understanding of the company's cash flow activities | Non-Cash Transaction (in thousands) | Six months ended Dec 31, 2023 | Six months ended Dec 31, 2022 | | :---------------------------------- | :---------------------------- | :---------------------------- | | Series C Preferred Stock common stock dividend | $173 | $362 | | Non-cash issue costs | — | $289 | | Subscriptions receivable | $103 | — | | Equipment additions reclassified from prepaid expenses | — | $447 | [9 Financial instruments](index=27&type=section&id=9%20Financial%20instruments) The company's financial instruments, including cash, receivables, and payables, are measured at fair value. The milestone payment liability, related to the REM-001 program, is classified as a Level 3 liability, indicating the use of unobservable inputs in its valuation - The company's milestone payment liability, related to the REM-001 program, is measured using Level 3 inputs, reflecting the use of unobservable estimates and assumptions[91](index=91&type=chunk) | Milestone Payment Liability (in thousands) | June 30, 2023 | December 31, 2023 | Change | | :--------------------------------------- | :------------ | :---------------- | :----- | | Balance | $166 | $179 | $13 | | Change in fair value estimate | - | $13 | $13 | [10 Subsequent events](index=27&type=section&id=10%20Subsequent%20events) Subsequent events include significant capital raises through the ATM facility, the final payment to a CRO following the termination of the VAL-083 study, the initiation of the REM-001 clinical study, and the assignment of VAL-083 rights to Valent with a retained royalty - From January 1, 2024, to February 12, 2024, the company raised an additional **$6,108 thousand** in net proceeds from the sale of **28,870 shares** of common stock under its ATM Facility[94](index=94&type=chunk) - On January 9, 2024, a final payment of **$400 thousand** was made to the CRO following the termination agreement for the VAL-083 study[97](index=97&type=chunk) - On February 12, 2024, the company announced the initiation of a 15-patient clinical trial for REM-001 in CMBC patients[98](index=98&type=chunk) - On February 13, 2024, the company assigned all rights to VAL-083 patents to Valent, retaining a **5% royalty** on Valent's subsequent commercialization[99](index=99&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.](index=30&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations.) This section provides management's perspective on Kintara Therapeutics' financial condition and operational results for the period ended December 31, 2023. It highlights the company's focus on REM-001 development, the termination of VAL-083, recent financing activities, and ongoing concerns about liquidity and Nasdaq listing compliance [Background](index=30&type=section&id=Background) Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel cancer therapies for unmet medical needs, with a primary focus on its lead candidate, REM-001, a photodynamic therapy for cutaneous metastatic breast cancer (CMBC) - Kintara Therapeutics is a clinical-stage biopharmaceutical company focused on developing new cancer therapies for patients with unmet medical needs[104](index=104&type=chunk)[107](index=107&type=chunk) - The company's lead candidate is REM-001, a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC)[108](index=108&type=chunk) [Recent Events](index=30&type=section&id=Recent%20Events) Recent events include securing a $2.0 million NIH grant for the REM-001 CMBC study, receiving Nasdaq notices for non-compliance with stockholders' equity and minimum bid price requirements, terminating the VAL-083 development due to poor study results, and initiating a strategic alternatives review process - Kintara was awarded a **$2.0 million NIH grant** effective July 1, 2023, to fund the majority of expenses for the REM-001 CMBC 15-patient clinical study[110](index=110&type=chunk) - The company received Nasdaq notices for non-compliance with the Stockholders' Equity Requirement (**$2,500,000 minimum**) and the Minimum Bid Price Requirement (**$1 per share minimum**) (December 13, 2023), with deadlines to regain compliance by **March 18, 2024**, and **June 10, 2024**, respectively[110](index=110&type=chunk)[117](index=117&type=chunk) - Preliminary topline results for VAL-083 from the GBM AGILE study did not show better performance than current standards of care, leading to the termination of VAL-083 development and a shift in focus to the REM-001 program[110](index=110&type=chunk) - In December 2023, the Board of Directors initiated a process to explore strategic alternatives to maximize stockholder value[117](index=117&type=chunk) [Upcoming Clinical Milestones](index=32&type=section&id=Upcoming%20Clinical%20Milestones) Following the receipt of the NIH grant, Kintara Therapeutics re-initiated its REM-001 program and expects to begin enrolling patients in the REM-001 Study in the first quarter of calendar year 2024 - The REM-001 program has been re-initiated, with patient enrollment in the REM-001 Study expected to begin in the **first quarter of calendar year 2024**[111](index=111&type=chunk) [REM-001](index=32&type=section&id=REM-001) REM-001 is a late-stage photodynamic therapy for cutaneous metastatic breast cancer (CMBC), showing an 80% complete response rate in prior studies. The program was re-initiated in July 2023 with a $2.0 million NIH grant, and a 15-patient Phase 2 study was initiated in February 2024 to optimize design for a future Phase 3 trial [Background](index=32&type=section&id=Background) REM-001 is a photodynamic therapy (PDT) for rare, unmet medical needs, specifically cutaneous metastatic breast cancer (CMBC). It consists of a laser light source, light delivery device, and the SnET2 drug product. Previous Phase 2/3 studies in CMBC patients showed an approximately 80% complete response rate, indicating its promise for local tumor elimination with minimal systemic effects - REM-001 is a photodynamic therapy (PDT) for cutaneous metastatic breast cancer (CMBC), consisting of a laser light source, light delivery device, and the SnET2 drug product[112](index=112&type=chunk)[115](index=115&type=chunk) - Analysis of data from four Phase 2/3 clinical studies in CMBC patients indicated an approximately **80% complete response rate** in evaluable tumor sites treated with REM-001 Therapy[113](index=113&type=chunk) - REM-001 Therapy offers advantages such as high tumor site direction, minimal systemic effects, compatibility with other therapies, and repeatability[114](index=114&type=chunk) [REM-001 Regulatory Filings](index=34&type=section&id=REM-001%20Regulatory%20Filings) Kintara received a 'Study May Proceed' letter from the FDA for its 15-patient REM-001 study in CMBC and has been granted Fast Track Designation for the program - The FDA granted a 'Study May Proceed' letter for the 15-patient REM-001 study in CMBC on August 9, 2022[118](index=118&type=chunk) - REM-001 has received Fast Track Designation (FTD) from the FDA for CMBC[118](index=118&type=chunk) [VAL-083](index=34&type=section&id=VAL-083) Kintara terminated the development of VAL-083 after preliminary topline results from the GBM AGILE study showed no improvement over current glioblastoma standards of care. The company subsequently assigned all rights to VAL-083 patents to Valent, retaining a 5% royalty on future net sales - Development of VAL-083 was terminated due to preliminary topline results from the GBM AGILE study indicating it did not perform better than current standards of care for glioblastoma[119](index=119&type=chunk) - All rights, title, and interest in VAL-083 patents were assigned to Valent, with Kintara retaining a **5% royalty** on Valent's subsequent commercialization of VAL-083[119](index=119&type=chunk) [Corporate History](index=34&type=section&id=Corporate%20History) Kintara Therapeutics, Inc. was formed in 2009, underwent a reverse acquisition in 2013, and merged with Adgero Biopharmaceuticals Holdings, Inc. in 2020, subsequently changing its name and listing on Nasdaq. The company operates through several wholly-owned subsidiaries focused on cancer drug development - Kintara Therapeutics, Inc. was formed in 2009, completed a reverse acquisition in 2013, and merged with Adgero Biopharmaceuticals Holdings, Inc. in 2020, leading to its current name and Nasdaq listing[120](index=120&type=chunk)[121](index=121&type=chunk) - The company operates as the parent of several clinical-stage subsidiaries, including Del Mar (BC) and Adgero, focused on cancer drug development[121](index=121&type=chunk)[105](index=105&type=chunk) [Outstanding Securities](index=34&type=section&id=Outstanding%20Securities) As of February 12, 2024, Kintara Therapeutics had 39,038 thousand shares of common stock outstanding, along with various warrants, stock options, restricted stock units, and convertible Series C Preferred Stock, representing potential future dilution | Security Type | Quantity (in thousands) | | :-------------------------- | :---------------------- | | Common stock outstanding | 39,038 | | Common stock warrants | 700 | | Series C Preferred Stock warrants | 2,444 (convertible into 42 common shares) | | Stock options | 237 | | Restricted stock units | 66 | | Series C Preferred Stock | 13,668 (convertible into 235 common shares) | [Selected Quarterly Information](index=34&type=section&id=Selected%20Quarterly%20Information) This section provides selected financial data from the balance sheets and statements of operations, highlighting key financial metrics and their changes over the reported periods [Selected Balance Sheet Data](index=35&type=section&id=Selected%20Balance%20Sheet%20Data) Kintara's balance sheet data shows a significant decline in cash and total assets, and a shift to negative working capital and stockholders' equity from June 30, 2023, to December 31, 2023, reflecting ongoing financial challenges | Metric (in thousands) | December 31, 2023 | June 30, 2023 | Change | | :-------------------- | :------------------ | :------------ | :----- | | Cash and cash equivalents | $658 | $1,535 | $(877) | | Working capital | $(684) | $188 | $(872) | | Total assets | $1,885 | $3,979 | $(2,094) | | Total stockholders' equity | $(164) | $731 | $(895) | [Selected Statement of Operations Data](index=35&type=section&id=Selected%20Statement%20of%20Operations%20Data) For both the three and six months ended December 31, 2023, Kintara Therapeutics reported significantly reduced net losses and lower research and development and general and administrative expenses compared to the prior year, leading to improved basic and fully diluted loss per share | Metric (in thousands, except per share) | 3 months ended Dec 31, 2023 | 3 months ended Dec 31, 2022 | 6 months ended Dec 31, 2023 | 6 months ended Dec 31, 2022 | | :------------------------------------ | :-------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | | Research and development | $111 | $2,059 | $1,970 | $5,230 | | General and administrative | $908 | $1,440 | $2,011 | $2,915 | | Net loss for the period | $(1,023) | $(3,454) | $(3,985) | $(8,050) | | Basic and fully diluted loss per share | $(0.24) | $(2.10) | $(1.37) | $(5.42) | [Expenses, net of non-cash, share-based compensation expense – non-GAAP](index=37&type=section&id=Expenses%2C%20net%20of%20non-cash%2C%20share-based%20compensation%20expense%20%E2%80%93%20non-GAAP) This non-GAAP disclosure provides a cash-basis view of research and development and general and administrative expenses, excluding non-cash, share-based compensation. For both the three and six months ended December 31, 2023, these net expenses were significantly lower than the prior year, reflecting reduced cash outlays for operations | Metric (in thousands) | 3 months ended Dec 31, 2023 | 3 months ended Dec 31, 2022 | 6 months ended Dec 31, 2023 | 6 months ended Dec 31, 2022 | | :-------------------------------------------------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | | Research and development net of non-cash, share-based compensation | $88 | $1,925 | $1,861 | $4,956 | | General and administrative net of non-cash, share-based compensation | $728 | $1,138 | $1,710 | $2,235 | [Results of Operations](index=37&type=section&id=Results%20of%20Operations) Kintara Therapeutics significantly reduced its net loss and operating expenses for both the three and six months ended December 31, 2023, compared to the prior year, primarily due to lower clinical development costs, reduced non-cash share-based compensation, and decreased professional fees and personnel costs [Comparison of the three months ended December 31, 2023, and December 31, 2022](index=37&type=section&id=Comparison%20of%20the%20three%20months%20ended%20December%2031%2C%202023%2C%20and%20December%2031%2C%202022) For the three months ended December 31, 2023, Kintara Therapeutics saw a substantial reduction in net loss and expenses, driven by a 95% decrease in R&D and a 37% decrease in G&A, largely due to lower clinical development costs and reduced share-based compensation | Metric (in thousands) | Dec 31, 2023 | Dec 31, 2022 | Change ($) | Change (%) | | :-------------------- | :----------- | :----------- | :--------- | :--------- | | Research and development | $111 | $2,059 | $(1,948) | -95% | | General and administrative | $908 | $1,440 | $(532) | -37% | | Net loss | $(1,023) | $(3,454) | $2,431 | -70.4% | - The decrease in R&D expenses was primarily due to lower clinical development costs for the GBM AGILE Study and reduced non-cash, share-based compensation, partially offset by **$198 thousand** in grant proceeds[131](index=131&type=chunk)[132](index=132&type=chunk) - The reduction in G&A expenses was mainly attributed to lower non-cash, share-based compensation, decreased professional fees, and reduced personnel costs[133](index=133&type=chunk) [Comparison of the six months ended December 31, 2023, and December 31, 2022](index=39&type=section&id=Comparison%20of%20the%20six%20months%20ended%20December%2031%2C%202023%2C%20and%20December%2031%2C%202022) For the six months ended December 31, 2023, Kintara Therapeutics achieved a 50.5% reduction in net loss, driven by a 62% decrease in R&D expenses and a 31% decrease in G&A expenses, reflecting lower clinical development costs, reduced share-based compensation, and decreased personnel costs | Metric (in thousands) | Dec 31, 2023 | Dec 31, 2022 | Change ($) | Change (%) | | :-------------------- | :----------- | :----------- | :--------- | :--------- | | Research and development | $1,970 | $5,230 | $(3,260) | -62% | | General and administrative | $2,011 | $2,915 | $(904) | -31% | | Net loss | $(3,985) | $(8,050) | $4,065 | -50.5% | - The decrease in R&D expenses was primarily due to lower clinical development costs for the GBM AGILE Study and reduced non-cash, share-based compensation, partially offset by **$210 thousand** in grant proceeds[136](index=136&type=chunk)[137](index=137&type=chunk) - The reduction in G&A expenses was mainly attributed to lower non-cash, share-based compensation and decreased personnel costs[139](index=139&type=chunk) - Preferred share dividends, including Series C Preferred stock dividends, decreased from **$362 thousand** in 2022 to **$173 thousand** in 2023[140](index=140&type=chunk) [Liquidity and Capital Resources](index=41&type=section&id=Liquidity%20and%20Capital%20Resources) Kintara Therapeutics significantly improved its cash flow from operating activities for the six months ended December 31, 2023, while increasing cash from financing activities through equity sales and grant funding. However, the company still faces substantial doubt about its ability to continue as a going concern, necessitating ongoing efforts to secure additional funding [Six months ended December 31, 2023, compared to the six months ended December 31, 2022](index=41&type=section&id=Six%20months%20ended%20December%2031%2C%202023%2C%20compared%20to%20the%20six%20months%20ended%20December%2031%2C%202022) For the six months ended December 31, 2023, Kintara Therapeutics significantly reduced cash used in operating activities by 60% and increased cash provided by financing activities by 39%, primarily through ATM facility sales and the Lincoln Park Purchase Agreement | Cash Flow Activity (in thousands) | Dec 31, 2023 | Dec 31, 2022 | Change ($) | Change (%) | | :-------------------------------- | :----------- | :----------- | :--------- | :--------- | | Operating activities | $(3,434) | $(8,530) | $5,096 | -60% | | Investing activities | $(20) | $(232) | $212 | 100% | | Financing activities | $2,577 | $1,856 | $721 | 39% | - Net cash used in operating activities decreased due to a lower net loss and changes in working capital, including the use of clinical trial deposits and settlement of accounts payable[142](index=142&type=chunk) - Net cash provided by financing activities increased due to **$2,476 thousand** from ATM facility sales and **$105 thousand** from the Lincoln Park Purchase Agreement, along with **$210 thousand** in clinical grant funding[144](index=144&type=chunk) [Going Concern and Management Plans](index=42&type=section&id=Going%20Concern%20and%20Management%20Plans) Kintara Therapeutics faces substantial doubt about its ability to continue as a going concern due to recurring losses, negative operating cash flows, and an accumulated deficit. Management is actively pursuing various financing alternatives, including equity offerings, grant funding, and strategic partnerships, while also exploring strategic alternatives to maximize shareholder value - The company reported a loss of **$3,985 thousand** and negative cash flow from operations of **$3,434 thousand** for the six months ended December 31, 2023, with an accumulated deficit of **$155,537 thousand** and cash of **$658 thousand**[146](index=146&type=chunk) - Substantial doubt exists about the company's ability to continue as a going concern within one year, necessitating significant additional funding for clinical trials, R&D, and general operations[148](index=148&type=chunk) - Management is pursuing financing through the ATM Facility (raising an additional **$6,108 thousand** from Jan 1 to Feb 12, 2024), Lincoln Park Purchase Agreement, grant funding, new equity, and strategic partnerships, while also exploring strategic alternatives[147](index=147&type=chunk)[149](index=149&type=chunk) [Critical Accounting Policies and Estimates](index=44&type=section&id=Critical%20Accounting%20Policies%20and%20Estimates) Kintara Therapeutics' critical accounting policies involve significant estimates for the fair value of financial instruments, particularly stock-based awards using the Black-Scholes model, and accruals for research and development expenses and clinical trials. These estimates require management judgment and are subject to potential material adjustments if actual results differ - The fair value of stock-based awards is estimated using the Black-Scholes option-pricing model, which relies on variables like expected volatility, exercise behavior, interest rates, and dividend yields, requiring significant management judgment[156](index=156&type=chunk) - Accruals for research and development expenses and clinical trials are estimated based on contract terms, discussions with personnel, and progress of trials, with adjustments made if actual results differ from estimates[158](index=158&type=chunk) [Off-Balance Sheet Arrangements](index=46&type=section&id=Off-Balance%20Sheet%20Arrangements) Kintara Therapeutics does not have any off-balance sheet arrangements - The company does not have any off-balance sheet arrangements[159](index=159&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk.](index=47&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk.) As a smaller reporting company, Kintara Therapeutics is not required to provide quantitative and qualitative disclosures about market risk - The company is not required to provide quantitative and qualitative disclosures about market risk as it is a smaller reporting company[160](index=160&type=chunk) [Item 4. Controls and Procedures.](index=47&type=section&id=Item%204.%20Controls%20and%20Procedures.) Kintara Therapeutics' principal executive and financial officers concluded that the company's disclosure controls and procedures were effective as of December 31, 2023. There were no material changes in internal control over financial reporting during the quarter - The principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective as of December 31, 2023[161](index=161&type=chunk) - No material changes in internal control over financial reporting occurred during the quarter ended December 31, 2023[163](index=163&type=chunk) [PART II - OTHER INFORMATION](index=48&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Item 1. Legal Proceedings.](index=48&type=section&id=Item%201.%20Legal%20Proceedings.) Kintara Therapeutics is not currently a party to any legal proceedings, nor is any of its property subject to such proceedings - There are no legal proceedings to which the company is a party or any of its property is subject[166](index=166&type=chunk) [Item 1A. Risk Factors.](index=48&type=section&id=Item%201A.%20Risk%20Factors.) Kintara Therapeutics faces significant risks related to its non-compliance with Nasdaq's stockholders' equity and minimum bid price requirements. Failure to regain compliance by the respective deadlines could lead to delisting, reduced liquidity, and hinder the company's ability to raise additional capital - The company is not in compliance with Nasdaq's Stockholders' Equity Requirement (**$2,500,000 minimum**) and Minimum Bid Price Requirement (**$1 per share minimum**)[169](index=169&type=chunk) - Deadlines to regain compliance are **March 18, 2024**, for stockholders' equity and **June 10, 2024**, for the minimum bid price[170](index=170&type=chunk)[171](index=171&type=chunk) - Failure to regain compliance could result in delisting from The Nasdaq Capital Market, which would negatively impact stock price, liquidity, and the ability to raise capital[172](index=172&type=chunk)[173](index=173&type=chunk) [Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.](index=48&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%2C%20Use%20of%20Proceeds%2C%20and%20Issuer%20Purchases%20of%20Equity%20Securities.) Kintara Therapeutics reported no unregistered sales of equity securities, use of proceeds, or issuer purchases of equity securities during the period - There were no unregistered sales of equity securities, use of proceeds, or issuer purchases of equity securities[174](index=174&type=chunk) [Item 3. Defaults Upon Senior Securities.](index=50&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities.) Kintara Therapeutics reported no defaults upon senior securities during the period - There were no defaults upon senior securities[175](index=175&type=chunk) [Item 4. Mine Safety Disclosures.](index=50&type=section&id=Item%204.%20Mine%20Safety%20Disclosures.) Mine safety disclosures are not applicable to Kintara Therapeutics - Mine safety disclosures are not applicable to the company[176](index=176&type=chunk) [Item 5. Other Information.](index=50&type=section&id=Item%205.%20Other%20Information.) On February 13, 2024, Kintara Therapeutics assigned all rights to VAL-083 patents to Valent, granting Valent a non-exclusive, fully-paid, royalty-free, perpetual, worldwide, and non-transferable license, while retaining a 5% royalty on Valent's subsequent net sales of VAL-083 - On February 13, 2024, the company assigned all rights to VAL-083 patents to Valent, granting a non-exclusive, fully-paid, royalty-free, perpetual, worldwide, and non-transferable license[177](index=177&type=chunk) - Kintara Therapeutics is entitled to receive royalties from Valent's subsequent commercialization of VAL-083, equal to **5% of Valent Net Sales**[177](index=177&type=chunk) [Item 6. Exhibits.](index=51&type=section&id=Item%206.%20Exhibits.) This section lists the exhibits filed or furnished as part of the Quarterly Report on Form 10-Q, including certifications, XBRL documents, and other required filings - The exhibit index includes certifications from the principal executive and financial officers (Sarbanes-Oxley Act Sections 302 and 906) and various Inline XBRL documents[181](index=181&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99-0360497 | | --- | --- | | ...

to FORM S-1 As filed with the Securities and Exchange Commission on October 27, 2023 Registration No. 333-274864 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 99-0360497 (I.R.S. Employer Identificatio ...

As filed with the Securities and Exchange Commission on October 27, 2023 Registration No. 333-274864 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 99-0360497 (I.R.S. Employer Identificatio ...

As filed with the Securities and Exchange Commission on October 24, 2023 Registration No. 333-274864 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 99-0360497 (I.R.S. Employer Identificatio ...

As filed with the Securities and Exchange Commission on October 24, 2023 Registration No. 333-274864 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 99-0360497 (I.R.S. Employer Identificatio ...

As filed with the Securities and Exchange Commission on October 4, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 99-0360497 (I.R.S. Employer Identification Number) 9920 Pacific Hei ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission file number 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99-0360497 | | --- | --- | | (State or o ...

[PART I - FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20-%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements.) The company's interim statements show a significant net loss and negative cash flow, raising substantial doubt about its going concern status Condensed Consolidated Interim Balance Sheet Highlights (in thousands) | Account | March 31, 2023 | June 30, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $3,045 | $11,780 | | Total current assets | $6,016 | $13,258 | | Total assets | $6,740 | $15,948 | | **Liabilities & Equity** | | | | Total current liabilities | $2,790 | $3,990 | | Total liabilities | $2,954 | $4,153 | | Total stockholders' equity | $3,786 | $11,795 | Condensed Consolidated Interim Statements of Operations Highlights (in thousands) | Metric | Three months ended Mar 31, 2023 | Nine months ended Mar 31, 2023 | | :--- | :--- | :--- | | Research and development | $2,005 | $7,235 | | General and administrative | $1,297 | $4,212 | | Net loss for the period | $(3,264) | $(11,314) | | Net loss attributable to common stockholders | $(3,266) | $(11,682) | | Basic and fully diluted loss per share | $(1.94) | $(7.32) | - The company's financial condition indicates **substantial doubt about its ability to continue as a going concern**, with a **loss of $11.3 million** and **negative cash flow from operations of $10.4 million**[27](index=27&type=chunk) - On November 10, 2022, the company executed a **1-for-50 reverse stock split** of its common stock, and all per-share data has been retrospectively restated[30](index=30&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=19&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations.) Management discusses its focus on cancer therapies, decreased operating expenses, and critically low liquidity reinforcing the going concern risk [Product Pipeline and Corporate Strategy](index=19&type=section&id=Product%20Pipeline%20and%20Corporate%20Strategy) The strategy centers on advancing the lead GBM drug VAL-083 while pausing the REM-001 program to conserve cash and exploring strategic options - The company's two lead candidates are **VAL-083 for glioblastoma (GBM)** and **REM-001 for cutaneous metastatic breast cancer (CMBC)**[92](index=92&type=chunk) - The REM-001 program was paused to conserve cash resources, with an expected savings of approximately **$3.0 million through calendar 2023**[132](index=132&type=chunk) - Topline results for the **VAL-083 GBM AGILE Study** are expected around the end of the fourth quarter of calendar 2023[94](index=94&type=chunk)[105](index=105&type=chunk) - The company is evaluating strategic options which may include raising additional capital, acquiring another company or assets, a sale, or other strategic partnerships[103](index=103&type=chunk) [Results of Operations](index=27&type=section&id=Results%20of%20Operations) Operating expenses decreased significantly year-over-year due to lower clinical development costs and reduced personnel expenses Comparison of Expenses for the Three Months Ended March 31 (in thousands) | Expense Category | 2023 | 2022 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | Research and development | $2,005 | $3,474 | $(1,469) | (42%) | | General and administrative | $1,297 | $1,884 | $(587) | (31%) | Comparison of Expenses for the Nine Months Ended March 31 (in thousands) | Expense Category | 2023 | 2022 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | Research and development | $7,235 | $11,169 | $(3,934) | (35%) | | General and administrative | $4,212 | $6,055 | $(1,843) | (30%) | - The decrease in R&D expenses was largely due to **lower clinical development costs** for the GBM AGILE Study and the pausing of the REM-001 program[148](index=148&type=chunk)[149](index=149&type=chunk)[154](index=154&type=chunk) - The decrease in G&A expenses was mainly a result of **lower non-cash, share-based compensation** and a reduction in personnel costs[150](index=150&type=chunk)[155](index=155&type=chunk) [Liquidity and Capital Resources](index=29&type=section&id=Liquidity%20and%20Capital%20Resources) The company's precarious financial position, with only $3.0 million in cash, creates substantial doubt about its ability to continue as a going concern Cash Flow Summary for the Nine Months Ended March 31 (in thousands) | Cash Flow Activity | 2023 | 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | $(10,357) | $(15,400) | | Net cash used in investing activities | $(232) | $0 | | Net cash provided by financing activities | $1,854 | $13,702 | - As of March 31, 2023, the company had **cash and cash equivalents of $3.0 million** and an **accumulated deficit of $148.0 million**[164](index=164&type=chunk) - The company received approximately **$1.86 million in net proceeds** from a stock purchase agreement, which is the maximum amount currently available under the agreement due to Nasdaq ownership limitations[161](index=161&type=chunk)[164](index=164&type=chunk) - The company's financial state indicates **substantial doubt about its ability to continue as a going concern**, and it will require additional funding to maintain operations[164](index=164&type=chunk)[165](index=165&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=32&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk.) This section is not applicable as the company qualifies as a smaller reporting company - Disclosure is not required for a smaller reporting company[175](index=175&type=chunk) [Item 4. Controls and Procedures](index=32&type=section&id=Item%204%20Controls%20and%20Procedures.) Disclosure controls and procedures were deemed effective, with no material changes to internal controls over financial reporting during the quarter - The company's disclosure controls and procedures were evaluated and **found to be effective** as of the end of the period covered by the report[176](index=176&type=chunk) - **No material changes** to the company's internal control over financial reporting were identified during the quarter ended March 31, 2023[178](index=178&type=chunk) [PART II - OTHER INFORMATION](index=33&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=33&type=section&id=Item%201.%20Legal%20Proceedings.) The company reports that it is not a party to any legal proceedings, nor is any of its property subject to such proceedings - The company is **not party to any legal proceedings**[181](index=181&type=chunk) [Item 1A. Risk Factors](index=33&type=section&id=Item%201A.%20Risk%20Factors.) No material changes to the risk factors previously disclosed in the company's Annual Report have been reported - **No material changes** to risk factors were reported since the last Annual Report on Form 10-K[182](index=182&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=33&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds.) The company reported no unregistered sales of equity securities during the period - None reported[183](index=183&type=chunk) [Item 3. Defaults Upon Senior Securities](index=33&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities.) The company reported no defaults upon senior securities - None reported[184](index=184&type=chunk) [Item 4. Mine Safety Disclosures](index=33&type=section&id=Item%204.%20Mine%20Safety%20Disclosures.) This item is not applicable to the company - Not applicable[185](index=185&type=chunk) [Item 5. Other Information](index=33&type=section&id=Item%205.%20Other%20Information.) The company reported no other information - None reported[186](index=186&type=chunk) [Item 6. Exhibits](index=34&type=section&id=Item%206.%20Exhibits.) This section lists filed exhibits, including officer certifications and Inline XBRL financial data files - The report includes certifications from the CEO and CFO pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act[187](index=187&type=chunk) - Inline XBRL Instance Documents and related taxonomy files are also included as exhibits[187](index=187&type=chunk)